AVACTA GROUP PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 45.5 GBX | +5.81% |
|
0.00% | -60.94% |
| May. 07 | AstraZeneca target raised; Antofagasta lowered | AN |
| May. 01 | Avacta picks Christina Coughlin to replace long-serving CEO | AN |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2023 | 23.25M 29.11M | Sales 2024 * | 24.5M 30.68M | Capitalization | 162M 202M |
|---|---|---|---|---|---|
| Net income 2023 | -24M -30.06M | Net income 2024 * | -27M -33.81M | EV / Sales 2023 | 14 x |
| Net cash position 2023 * | 16.2M 20.29M | Net cash position 2024 * | 22.4M 28.05M | EV / Sales 2024 * | 5.68 x |
| P/E ratio 2023 |
-12.7
x | P/E ratio 2024 * |
-5.88
x | Employees | 120 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 70.66% |
More Fundamentals
* Assessed data
More news
Latest transcript on Avacta Group Plc
More recommendations
More press releases
| 1 day | +5.81% | ||
| Current month | -0.55% | ||
| 1 month | -12.08% | ||
| 3 months | -53.57% | ||
| 6 months | -69.05% | ||
| Current year | -60.94% |
1 week
43.00
46.50
1 month
43.0052.10
Current year
43.00119.85
1 year
43.00166.98
3 years
38.00275.00
5 years
13.00291.80
10 years
13.00291.80
| Managers | Title | Age | Since |
|---|---|---|---|
Tony Gardiner
DFI | Director of Finance/CFO | 53 | 16-01-03 |
Matt Johnson
CTO | Chief Tech/Sci/R&D Officer | - | 13-09-15 |
Michael Vinegrad
IRO | Public Communications Contact | - | 14-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Trevor Nicholls
BRD | Director/Board Member | 67 | 13-08-01 |
Tony Gardiner
DFI | Director of Finance/CFO | 53 | 16-01-03 |
Paul Fry
BRD | Director/Board Member | 58 | 20-02-02 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 45.5 | +5.81% | 2,863,172 |
| 24-05-09 | 43 | -3.80% | 2,035,236 |
| 24-05-08 | 44.7 | -0.89% | 3,315,287 |
| 24-05-07 | 45.1 | -0.88% | 3,413,113 |
Delayed Quote London S.E., May 10, 2024 at 11:35 am EDT
More quotes
Avacta Group plc is a United Kingdom-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. The Company has two segments: Therapeutics and Diagnostics. The Therapeutics segment is a clinical stage oncology biotech division harnessing therapeutic platforms to develop novel, highly targeted cancer drugs. The Diagnostics segment is focused on supporting healthcare professionals and broadening access to diagnostics. It has two platforms: preICISION and Affimer. The Company's preICISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preICISION platform harnesses this tumor specific protease to activate preICISION peptide drug conjugates and preICISION antibody/Affimer drug conjugates in the tumor microenvironment. Its lead preICISION program AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies.
Calendar
2024-09-25
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
0.455
GBP
Average target price
0.8233
GBP
Spread / Average Target
+80.95%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -60.94% | 202M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- AVCT Stock